Data Sheet (Cat.No.T1806)

TargetMol

IDO-IN-7

Chemical Properties



CAS No. : 1402836-58-1

Formula: C18H22N2O

Molecular Weight: 282.38

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	IDO-IN-7 (NLG-919 analogue) is a potent inhibitor of the IDO (indoleamine-(2, 3)-dioxygenase) pathway.
Targets(IC50)	IDO,Indoleamine 2,3-Dioxygenase (IDO)
In vitro	In mice bearing B16F10 tumors, NLG919 significantly enhanced the antitumor response of pmel-1 resting cells to homologous hgp100 peptide and CpG-1826.
In vivo	NLG919 effectively blocks the IDO-induced suppression of T-cell responses, restoring T-cell activity (ED50=80 nM). In mouse dendritic cells (DCs) expressing IDO from tumor lymph nodes (ED50=120 nM), NLG919 abolishes the IDO-induced inhibition of antigen-specific T-cells (OT-1).

Solubility Information

Solubility	Ethanol: 26 mg/mL (92.07 mM),Sonication is recommended. DMSO: 48 mg/mL (169.98 mM),Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.08 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.5413 mL	17.7066 mL	35.4133 mL
5 mM	0.7083 mL	3.5413 mL	7.0827 mL
10 mM	0.3541 mL	1.7707 mL	3.5413 mL
50 mM	0.0708 mL	0.3541 mL	0.7083 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

AACR Meeting, Poster 491, 2013.
Nguyen D J M, Theodoropoulos G, Li Y Y, et al. Targeting the kynurenine pathway for the treatment of cisplatin resistant lung cancer. Molecular Cancer Research. 2019: molcanres. 0239.2019
Zhou Y, Lu X, Du C, et al. Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies[J]. Bioorganic & Medicinal Chemistry Letters. 2021, 34: 127756.
Zhou Y, Lu X, Du C, et al. Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies. Bioorganic & Medicinal Chemistry Letters. 2021, 34: 127756.
Nguyen D J M, Theodoropoulos G, Li Y Y, et al. Targeting the kynurenine pathway for the treatment of cisplatin resistant lung cancer[J]. Molecular Cancer Research. 2019: molcanres. 0239.2019.
Nguyen D J M, Theodoropoulos G, Li Y Y, et al. Targeting the kynurenine pathway for the treatment of cisplatin-resistant lung cancer[J]. Molecular Cancer Research. 2020, 18(1): 105-117.